New hope for cancer patients: drug targets wasting syndrome

NCT ID NCT07243379

Recruiting now Symptom relief Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated Jun 17, 2026 · Updated 34 times

Summary

This study looks at how well a drug called nanocrystalline megestrol acetate works for cancer patients who have cachexia, a condition causing severe weight loss and appetite loss. About 495 adults with cancer and cachexia will take the drug and be monitored for up to 12 weeks. The main goal is to see if their appetite improves after 4 weeks, with secondary goals of checking for weight gain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF MALIGNANT TUMOR CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Henan Cancer Hospital, Affiliated to Zhengzhou University
RECRUITING

Zhengzhou, Henan, 45000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF MALIGNANT TUMOR CACHEXIA MULTICENTER OBSERVATIONAL STUDY MULTICENTER OBSERVATIONAL STUDY